Pharma Journalist -

Sanofi and Innate Pharma SA announced an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM …
Read More...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced…
Read More...

BIOASIS TECHNOLOGIES INC., a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated,…
Read More...

Fresenius Kabi announced the immediate availability in the U.S. of Lacosamide Injection, USP, a generic equivalent to VIMPAT. Fresenius Kabi Lacosamide Injection, USP is an approved…
Read More...

Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments for depression and other mental health disorders, announced the closing…
Read More...

The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are…
Read More...

Eisai Co., Ltd. announced that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration agreement aiming to create…
Read More...

Filament Health Corp. a clinical-stage natural psychedelic drug development company, and Psyence Group Inc, a life science biotechnology company pioneering the use of natural psilocybin…
Read More...

Ono Pharmaceutical Co., Ltd. announced that it has entered into a multi target R&D collaboration agreement with PrecisionLife Limited, a global techbio company generating the…
Read More...

Exicure, Inc. an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, announced the…
Read More...